Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases

Plasencia-García, Beatriz Oda; Rico-Rangel, María Isabel; Rodríguez-Menéndez, Gonzalo; Rubio-García, Ana; Torelló-Iserte, J.; Crespo‐Facorro, Benedicto

doi:10.1055/a-1492-3293

Cited by 15 publications

(19 citation statements)

References 47 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The standards of prescription improved after the intervention of the LPTs. The added difficulty of changes in specific treatments for COVID and its interactions with psychotropic drugs should be noted ( Plasencia-García et al, 2021 ). The challenge of implementing new treatment and follow-up programs, for example, for healthcare personnel, should also be considered.…”

Section: Discussionmentioning

confidence: 99%

Liaison psychiatry before and after the COVID-19 pandemic

E¹,

Alonso-Sanchez²,

Ayuso-Mateos³

et al. 2022

Psychiatry Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Liaison psychiatry before and after the COVID-19 pandemic

E¹,

Alonso-Sanchez²,

Ayuso-Mateos³

et al. 2022

Psychiatry Research

View full text Add to dashboard Cite

“…Lithium is contraindicated for concurrent use with hydroxychloroquine, chloroquine, and azithromycin. Anticonvulsants and benzodiazepines present little or no risk for adverse interaction with COVID-19 treatments [54].…”

Section: Pain Management In Covid-19mentioning

confidence: 99%

Pain Management and COVID-19: A Latin American Perspective

Guerrero¹,

Castromán²,

Quiroga³

et al. 2022

Cureus

View full text Add to dashboard Cite

Vaccinations and therapeutics have been developed for COVID-19, but vaccine uptake varies markedly among countries. Public health responses have also varied, in particular, with lockdown efforts and school closing. All over the world, the pandemic exposed healthcare and economic weaknesses. COVID-19 exacerbated mental health issues by exposing the population to prolonged periods of fear, anxiety, financial stress, psychological uncertainties, and sometimes isolation from even family and friends. Chronic pain patients have been disproportionately affected. The pandemic-associated stresses may have exacerbated their already painful symptoms while at the same time interrupting their access to care. The ramifications of the COVID-19 post-viral syndrome ("long are not yet known. COVID-19 viral infection has been associated with neuropathic pain symptoms. Tele-triage and telehealth applications can help manage chronic pain patients in the COVID-19 era, but many interventional procedures, injections, or other treatments have been delayed. The role of palliative care for patients with terminal cases of infection must be re-examined. Palliative care is a relatively new medical specialty and allows terminally ill patients to die in as much comfort and peace as can be afforded to them. More training in palliative care for all clinicians is urgently needed. COVID-19 exposed much that is wrong or weak or inadequate in our healthcare systems, but it also allowed us to embrace new technologies and develop better systems to manage the challenge of a pandemic.

show abstract

“…cardiovascular and metabolic disorders, coagulopathies, immunological disorders, etc. ), and possible drug interactions that can result in either reduced drug tolerance, efficacy or safety [43,44,75], caution should be paid when prescribing specific classes of drugs in psychiatric patients. Studies on drug safety and effectiveness in people with pre-existent mental disorders and using psychopharmacological treatments are required.…”

Section: Pharmacological Treatment Options For Covid-19 For People Wi...mentioning

confidence: 99%

Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health

et al. 2022

View full text Add to dashboard Cite

As COVID-19 becomes endemic, identifying vulnerable population groups for severe infection outcomes and defining rapid and effective preventive and therapeutic strategies remains a public health priority. We performed an umbrella review, including comprehensive studies (meta-analyses and systematic reviews) investigating COVID-19 risk for infection, hospitalization, Intensive Care Unit (ICU) admission, and mortality in people with psychiatric disorders, and outlined evidence-and consensus-based recommendations for overcoming potential barriers that psychiatric patients may experience in preventing and managing COVID-19, and defining optimal therapeutic options and current research priorities in psychiatry. We searched Web of Science, PubMed, and Ovid/PsycINFO databases up to 17 January 2022 for the umbrella review. We synthesized evidence, extracting when available pooled odd ratio estimates for the categories 'any mental disorder' and 'severe mental disorders'. The quality of each study was assessed using the AMSTAR-2 approach and ranking evidence quality. We identified four systematic review/meta-analysis combinations, one metaanalysis, and three systematic reviews, each including up to 28 original studies. Although we rated the quality of studies from moderate to low and the evidence ranged from highly suggestive to nonsignificant, we found consistent evidence that people with mental illness are at increased risk of COVID-19 infection, hospitalization and most importantly mortality, but not of ICU admission. The risk and the burden of COVID-19 in people with mental disorders, in particular those with severe mental illness, can no longer be ignored but demands urgent targeted and persistent action. Twentytwo recommendations are proposed to facilitate this process.

show abstract

Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases

Cited by 15 publications

References 47 publications

Liaison psychiatry before and after the COVID-19 pandemic

Liaison psychiatry before and after the COVID-19 pandemic

Pain Management and COVID-19: A Latin American Perspective

Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health

Contact Info

Product

Resources

About